The arrival of the Moderna coronavirus vaccine in the UK in April 'adds another string to our bow' says Professor Adam Finn from the University of Bristol, who sits on the Joint Committee on Vaccination and Immunisation (JCVI). The US vaccine has been approved for use in the UK and would be the third to be rolled out after Oxford/AstraZeneca and Pfizer.
ADAM FINN: So the arrival of the Moderna vaccine adds-- adds a further line of supply to enable the vaccine program to move forward into the under 50s. I think we've all been clear from the outset that the quantities that Moderna are capable of providing are likely to be many fewer doses than we're seeing for AstraZeneca and Pfizer, partly because they're a smaller outfit, and partly because they're primarily directing their supplies towards the US rather than Europe.
So I don't think this is a game-changer; I think it's an incremental change. It adds another string to our bow, if you like. And we-- we-- it gives us an extra line of security, but it's not a profoundly different change of direction.